Nykode Therapeutics shares rise on new VB-C-03 trial data
- ByInvesting.com-
Investing.com - Nykode Therapeutics ASA (OSE:NYKD) announced new interim data from its VB-C-03 trial on Tuesday. The company...
Last | High | Low | |||||
|---|---|---|---|---|---|---|---|
| 15.84 | 15.84 | 15.58 | +0.14 | +0.89% | 1.82M | ||
| 138.60 | 138.60 | 134.00 | +5.00 | +3.74% | 477.54K | ||
| 87.58 | 88.30 | 87.00 | +0.18 | +0.21% | 3.21M | ||
| 230.60 | 231.40 | 224.00 | +7.20 | +3.22% | 1.36M | ||
| 342.10 | 342.10 | 332.50 | +16.20 | +4.97% | 1.93M | ||
| 130.50 | 131.20 | 129.90 | +0.30 | +0.23% | 1.4M | ||
| 0.324 | 0.399 | 0.323 | -0.032 | -8.99% | 907.54K | ||
| 280.20 | 281.30 | 277.80 | +2.70 | +0.97% | 2.85M | ||
| 116.40 | 117.40 | 115.40 | -0.60 | -0.51% | 709.67K | ||
| 177.60 | 182.30 | 177.50 | -5.00 | -2.74% | 1.19M | ||
| 173.90 | 175.40 | 173.30 | +0.30 | +0.17% | 1.02M | ||
| 464.70 | 471.70 | 461.70 | -0.80 | -0.17% | 352.35K | ||
| 257.60 | 262.60 | 255.60 | +0.20 | +0.08% | 350.79K | ||
| 112.80 | 113.80 | 111.20 | +0.40 | +0.36% | 263.21K | ||
| 299.00 | 302.80 | 298.40 | -5.00 | -1.64% | 1.47M | ||
| 387.60 | 391.70 | 383.00 | -4.10 | -1.05% | 878.4K | ||
| 326.00 | 328.00 | 314.50 | +11.00 | +3.49% | 94.55K | ||
| 907.00 | 920.00 | 907.00 | -8.00 | -0.87% | 29.47K | ||
| 8.13 | 8.25 | 8.10 | -0.09 | -1.09% | 263.65K | ||
| 143.00 | 144.80 | 142.80 | -1.60 | -1.11% | 207.87K | ||
| 466.00 | 471.60 | 455.40 | +9.20 | +2.01% | 148.84K | ||
| 284.10 | 285.90 | 281.70 | +0.30 | +0.11% | 878.58K | ||
| 268.80 | 268.80 | 263.40 | -0.60 | -0.22% | 559.2K | ||
| 2.17 | 2.19 | 2.11 | +0.03 | +1.40% | 1.78M | ||
| 50.50 | 51.40 | 50.05 | +2.46 | +5.12% | 1.87M | ||
| 141.50 | 143.20 | 140.20 | +0.30 | +0.21% | 571.99K | ||
| 16.85 | 17.14 | 16.85 | -0.24 | -1.40% | 3.76M | ||
| 590.00 | 591.50 | 569.00 | +19.00 | +3.33% | 346.97K | ||
| 193.40 | 194.40 | 190.60 | +1.80 | +0.94% | 57.55K | ||
| 127.40 | 129.80 | 126.80 | -0.10 | -0.08% | 313.81K | ||
| 166.30 | 167.90 | 164.60 | -0.10 | -0.06% | 310.33K | ||
| 8.31 | 8.40 | 8.12 | -0.04 | -0.48% | 1.13M | ||
| 190.40 | 191.00 | 187.00 | +2.40 | +1.28% | 65.34K | ||
| 266.00 | 279.00 | 264.00 | -8.50 | -3.10% | 47K | ||
| 57.90 | 58.80 | 57.80 | -0.80 | -1.36% | 26.16K | ||
| 23.00 | 23.40 | 22.90 | -0.40 | -1.71% | 18.55K | ||
| 2.03 | 2.05 | 2.01 | 0.00 | 0.00% | 5.5M | ||
| 49.15 | 50.20 | 48.90 | -0.75 | -1.50% | 255.84K | ||
| 208.00 | 211.50 | 208.00 | -4.00 | -1.89% | 200.75K | ||
| 176.60 | 178.20 | 176.40 | +0.40 | +0.23% | 44.2K | ||
| 108.00 | 110.10 | 105.30 | +1.00 | +0.93% | 952.19K | ||
| 120.20 | 121.10 | 119.70 | +0.10 | +0.08% | 188.74K | ||
| 114.60 | 114.80 | 113.60 | +0.60 | +0.53% | 232.81K | ||
| 39.72 | 40.98 | 39.70 | -0.68 | -1.68% | 613.03K | ||
| 232.20 | 234.20 | 230.20 | -4.00 | -1.69% | 516.22K | ||
| 90.10 | 90.10 | 88.80 | +1.10 | +1.24% | 250.75K | ||
| 119.60 | 121.00 | 118.60 | -1.60 | -1.32% | 63.75K | ||
| 23.65 | 24.10 | 23.60 | -0.40 | -1.66% | 188.72K | ||
| 31.15 | 31.90 | 31.05 | -0.45 | -1.42% | 788.62K | ||
| 29.86 | 30.44 | 29.56 | +0.06 | +0.20% | 1.14M | ||
| 21.89 | 22.09 | 20.04 | +1.63 | +8.05% | 9.65M | ||
| 16.00 | 17.00 | 15.70 | -1.40 | -8.05% | 39.12K | ||
| 69.86 | 70.00 | 69.08 | +1.06 | +1.54% | 547.69K | ||
| 12.00 | 12.20 | 11.96 | 0.00 | 0.00% | 61.52K | ||
| 62.40 | 62.40 | 60.70 | +0.35 | +0.56% | 395.62K | ||
| 1.10 | 1.22 | 0.98 | +0.08 | +7.84% | 1.13M | ||
| 0.04 | 0.04 | 0.04 | 0.00 | 0.00% | 2.14M | ||
| 11.56 | 11.75 | 11.32 | -0.23 | -1.95% | 7.97M | ||
| 121.10 | 121.90 | 118.60 | +0.40 | +0.33% | 1.06M | ||
| 35.00 | 35.07 | 34.55 | +0.33 | +0.95% | 4.95M | ||
| 3.61 | 4.10 | 3.43 | +0.05 | +1.41% | 3.36M |
Investing.com - Nykode Therapeutics ASA (OSE:NYKD) announced new interim data from its VB-C-03 trial on Tuesday. The company...
Investing.com -- Moody’s Ratings affirmed Telenor ASA’s Baa1 senior unsecured ratings on Friday while changing the outlook to...
Investing.com -- In its February report, BofA Research highlights diverging consumer demand trends across European IT Hardware,...
Lower oil prices are squeezing Big Oil earnings, with crude around $60 per barrel undermining the sustainability of shareholder...
2022 was a dismal year for both bonds and stocks In the final quarter of the year, the dollar also joined the party and...
No Earning Reports have been scheduled